Retrospective chart review evaluates adverse events in children with atopic dermatitis on dupilumab, highlighting vaccine safety implications.
Dupilumab is an IL‐4R α and IL‐13 inhibitor FDA‐approved for the treatment of atopic dermatitis (AD) in patients 6 months and older. Guidelines recommend against live‐attenuated vaccines due to limited safety data. We conducted a retrospective chart review of 233 patients aged 6 months to 10 years receiving dupilumab for AD at Children's Wisconsin, which showed that 19 received live vaccines during the study period. Four patients reported adverse events, including one requiring hospitalization. This study aims to evaluate the effects of live vaccines in children on dupilumab therapy and to assess associated adverse events, including in patients receiving their primary series of vaccines, a setting not previously described.
No takes yet. Share an insight, caveat, or question.
Bruess et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: